Actelion Awarded the prix Hermes de l'innovation
Thursday, 31.03.2011

Actelion Awarded the prix Hermes de l'innovation

Actelion today announced that the company will receive this year's Prix Hermès de l'Innovation in the category "amélioration de la condition humaine" (improvement in the conditions of human life).

 The European Institute for Creative Strategies and Innovation awards the Prix Hermès annually to selected institutions and companies in recognition of their outstanding innovative achievements in different areas of life. It includes a total of eight different categories. The award ceremony will take place in Paris on April 19th.

 

Actelion receives the Prix Hermès for its extensive innovative research work for improving the quality of life of patients. In particular, the Prize recognizes Actelion's commitment to improve treatment of children with rare diseases, especially in pulmonary arterial hypertension.

 

Marc Giget, founder and scientific director of the European Institute for Creative Strategies and Innovation, explained that "Actelion is being awarded the prize in the category "Improvement in the conditions of life" in recognition of its overall innovative achievements as a leading company in the biotech sector. Since it was founded, Actelion has remained true to its corporate philosophy and now markets four medicines with which a great many patients have been helped."

 

The European Institute for Creative Strategies and Innovation is a Paris-based think-tank dedicated to the research and dissemination of innovative ideas and strategies in Europe and the rest of the world.

 

Actelion

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®).


Contact:

Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com

back to list